Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development. It also offers formulation design and 3D pharmaceutical processing services. Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei City, Taiwan.
Frequently asked questions
What sector does Mercury Biopharmaceutical Corporation (6932) operate in?
Mercury Biopharmaceutical Corporation belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Mercury Biopharmaceutical Corporation (6932) current stock price?
As of the latest data, Mercury Biopharmaceutical Corporation stock price is NT$6.20, with a previous close of NT$6.17. Mercury Biopharmaceutical Corporation gained NT$0.03 in the last trading session, representing a 0.49% increase.
What is Mercury Biopharmaceutical Corporation (6932) current market capitalization?
Mercury Biopharmaceutical Corporation market cap is approximately 2.59 billion.
What is Mercury Biopharmaceutical Corporation (6932) Earnings Per Share (EPS)?
The trailing EPS is -NT$0.16.
Does Mercury Biopharmaceutical Corporation (6932) pay dividends?
No. Mercury Biopharmaceutical Corporation does not pay a dividend.
What is Mercury Biopharmaceutical Corporation (6932) beta (volatility) score?
Mercury Biopharmaceutical Corporation has a beta of -1.116, indicating lower volatility than the overall market.
